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Abstract
A range of antimalarial drugs were procured from private pharmacies in urban and peri-urban areas in the major cities of six
African countries, situated in the part of that continent and the world that is most highly endemic for malaria. Semi-
quantitative thin-layer chromatography (TLC) and dissolution testing were used to measure active pharmaceutical
ingredient content against internationally acceptable standards. 35% of all samples tested failed either or both tests, and
were substandard. Further, 33% of treatments collected were artemisinin monotherapies, most of which (78%) were
manufactured in disobservance of an appeal by the World Health Organisation (WHO) to withdraw these clinically
inappropriate medicines from the market. The high persistence of substandard drugs and clinically inappropriate
artemisinin monotherapies in the private sector risks patient safety and, through drug resistance, places the future of
malaria treatment at risk globally.
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Introduction
Malaria surged in sub-Saharan Africa in the 1990s, due in part
to increased resistance to chloroquine and sulfadoxine-pyrimeth-
amine (SP).[1] Exposure to substandard antimalarial drugs likely
exacerbated this trend.[2,3,4] Pressure from malaria scientists
prompted wholesale adoption of artemisinin-based combination
therapies (ACTs) by endemic country governments and donors.[5]
In January 2006, the WHO issued new treatment guidelines for
the first time in 20 years recommending ACTs for the treatment of
uncomplicated malaria. The WHO further called to end the
production and marketing of artemisinin monotherapies in order
to protect these formulations against parasitic resistance. Accord-
ing to the WHO’s antimalarial drug quality database, every
national treatment policy in sub-Saharan Africa except Swaziland
and Cape Verde now recommends treating uncomplicated
malaria with ACTs.
These well-intentioned changes might remain unrealized and
vulnerable. Substandard ACTs, and ‘‘legitimate’’ artemisinin
monotherapies, are unparalleled threats driving clinical failure of
malaria treatment.[6,7,8] Especially in Sub-Saharan Africa,
governments lack the ability through customs and policing to
stop these medicines entering the private market, where many
(oftentimes most) persons buy their treatment.[9,10] Unless these
medicines are of a consistently high quality, the great strides made
in recent years to transition from chloroquine and SP to ACTs
could be imperiled by drug resistance. This study is the first to
sample the quality of medicines throughout the geographic band
of hyper- and holoendemic P. falciparum malaria which stretches
unbroken from West, to Central, to East Africa—the world’s
worst.[11]
Results
195 treatment packs were tested, producing 210 sample results.
The difference between tests and results is explained in that co-
packaged, but not co-formulated ACTs, such as artesunate and
amodiaquine were tested as individual monotherapies.
Overall 35% (73/210) of tested samples were substandard and
failed either TLC or dissolution tests (See Table 1). Of the specific
pharmaceutical types, failure by TLC, dissolution or both,
occurred in 38% of SP, 48% of amodiaquine, 24% of mefloquine,
31% of artesunate, 27% of artemether, 55% of dihydroartemisinin
and 19% of artemether-lumefantrine fixed-dose combinations.
Artemisinin monotherapy, which the WHO rejects as inher-
ently substandard treatment even when its dosage is correct,
remains common in Africa. 33% (64/195) of all treatment packs
tested were artemisinin monotherapies, and 42% (27/64) failed
either TLC or dissolution tests. 78% (50/64) were manufactured
after the WHO’s January 2006 appeal to halt monotherapy
production. A further sign that certain manufacturers of
artemisinin monotherapies do not take clinical efficacy seriously
was the tremendous heterogeneity in expiry dates: 10 listed an
expiration date of two years, while most (42/64) listed three years.
Five listed an expiration date of four years, and seven lacked either
a manufacture date or both a manufacture date and expiration
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in this study were forwarded to the WHO.
The authors did not attempt a forensic examination of
trademarks or product designs to differentiate between products
that were merely substandard and those which were deliberately
counterfeited, as neither is clinically suitable. However, there was
an apparent trend in that failing products more often originated or
were claimed to originate from poorer parts of the world with
weaker regulatory systems: failure rates were 48% (30/63) for
Africa, 32% (29/90) for Asia and 24% (12/50) for Europe (See
Table 2). Only four US-manufactured samples were tested; none
failed.
Discussion
This study sheds light on the availability and relative quality of
private sector antimalarials in Africa’s private sector. In countries
situated in the world’s most intense region of holoendemic and
hyperendemic P. falciparum malaria, where the difference between
a proper and a bogus medicine cannot be surpassed, various
substandard therapies and clinically inappropriate monotherapies
remain widely available, with between a quarter and over half of
products sold in urban and peri-urban pharmacies failing basic
quality testing. We do not quantitatively estimate the public health
impact of this crisis, but it must be staggering.
The WHO has taken diplomatic steps to fight this problem. It
coordinates a passive reporting system for substandard medicines,
for example, and World Health Assembly Resolution WHA60.18
of May 2007 committed member states to cease production and
marketing of artemisinin monotherapies. Our study results suggest
these diplomatic efforts alone are not making a sufficient impact in
the field. To be effective, the WHO needs its partners to support
policy change, which we describe here.
Other international agencies must apply leverage, apart from
the WHO’s sole diplomatic efforts. Major financiers of malaria
treatment, such as the Global Fund and the World Bank, should
make aid conditional on countries de-listing oral artemisinin
monotherapies from national formularies. The World Trade
Organisation, which sets the rules of global commerce, should
enact rules prohibiting the international trade in artemisinin
monotherapies and reducing the tariffs on proper medicines to
zero. These steps will ensure that less money flows to the
inappropriate monotherapies, and that ACTs are made less
expensive. The political traction to accomplish these steps should
come from the Group of Eight leading industrial countries, who
declared ACTs a global priority in 2005.
Effort must also be made to reverse the various initiatives which
now spend public money on inadequately regulated medicines.
The Global Fund, for example, finances the purchase of medicines
whose quality is not approved by the WHO’s prequalification
scheme or any developed country’s regulatory authority–known as
‘‘Option C’’ medicines. According to an internal report published
by the Wall Street Journal, the World Bank recently discovered in
an audit that malaria medicines it purchased in India from a local
manufacturer were clinically substandard.
These incidents argue strongly for a rule against purchasing
locally-manufactured medicines, except where those medicines
have received regulatory approval from a developed country or
the WHO’s prequalification scheme. The WHO’s current
practice, which regards a medicine as good enough if it has
applied for prequalification, but not necessarily passed the WHO
quality standards and received prequalification, is an unprincipled
distortion of the rules. Similarly stringent rules must inure to the
proposed $1.9 billion Affordable Medicines Facility for malaria,
which intends to provide clinically effective ACTs at retail outlets
where they are needed. Unless this initiative employs standards
higher than the current Global Fund and World Bank ones and
strengthens post-market surveillance, it risks to expand the supply
of the substandard and inappropriate treatments found in this
study, which would be disastrous in clinical and drug resistance
terms both.[13]
Further, this study demonstrates that at the local level, the
capacity for basic drug quality tests to strengthen post-market
surveillance can be deployed with relative ease. A MinilabH or
equivalent technology costs about $4,000, requires modest
training, and can be run in an ordinary air-conditioned room.
Table 1. Testing results by formulation and country purchased for TLC and dissolution
i,ii
Ghana Kenya Nigeria Rwanda Tanzania Uganda Total
Sulfadoxine-pyrimethamine 50% (3/6) 38% (6/16) 50% (1/2) 50% (3/6) 27% (3/11) 33% (3/9) 38% (19/50)
Amodiaquine 33% (2/6) 50% (4/8) 25% (1/4) - 100% (2/2) 56% (5/9) 48% (14/29)
Mefloquine 0% (0/1) - 50% (1/2) - 0% (0/3) 27% (3/11) 24% (4/17)
Artesunate 38% (3/8) 0% (0/4) 33% (2/6) - 31 (4/13) 33% (6/18) 31% (15/49)
Artemether 0% (0/3) 100% (1/1) - - - 29% (2/7) 27% (3/11)
Dihydro-artemisinin 40% (2/5) 56% (5/9) 100% (1/1) - 50% (2/4) 67% (2/3) 55% (12/22)
Artemether-lumefantrine fixed-dose
combination
38% (3/8) 0% (0/4) 14% (1/7) 0% (0/3) 0% (0/1) 22% (2/9) 19% (6/32)
Total 35% (13/37) 38% (16/42) 32% (7/22) 33% (3/9) 32% (11/34) 35% (23/66) 35% (73/210)
i.Percentages are supported by (total that failed either dissolution or TLC/total treatments tested)
ii.Co-packaged ACTs are listed as individual monotherapies
doi:10.1371/journal.pone.0002132.t001










Africa 30 63 48%
Asia 29 90 32%
Europe 12 50 24%
US 0 4 0%
iii.Manufacturer information not available for 3 tested sampless
doi:10.1371/journal.pone.0002132.t002
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ratio of 0.1%) is about $2, and can be completed in under an hour.
Training programs for district level malaria officers and regulatory
officials in Southeast Asia could be replicated in sub-Saharan
Africa.[14] Such simple and cheap technology should be
distributed more widely, to the ministry of health, police, customs
services and non-governmental organizations. A decentralized
effort of this kind, with drug quality watchdogs at several layers of
government and in civil society, could be effectively tried in a
country for only tens of thousands of dollars.
Materials and Methods
A simple sampling protocol was developed in line with similar
studies.[12] Antimalarial drugs were obtained by local nationals
from randomly selected private pharmacies in the major cities of
six African countries within the high endemicity band. Study
agents posed as customers were asked to purchase a sample lot of
antimalarial tablet formulations available, namely: SP, amodia-
quine, mefloquine, artemisinin monotherapies and any ACTs.
Agents were instructed not to purchase chloroquine. Treatment
packs were maintained either in the manufacturer’s original
packaging or loose, and stored at ambient temperature until
testing. Tests were completed within 40 days of sample collection.
The Global Pharma Health Fund e.V. MinilabH was used to
run semi-quantitative thin-layer chromatography (TLC) and
dissolution tests on each sample to determine the presence and
relative concentration of active ingredients. Each test was run in
duplicate, with the generous assumption that the result more
consistent with the reference was recorded. The MinilabH
protocols award products a ‘‘pass’’ if they have 80% or more of
the labeled active ingredient(s) (note there is no upper-bound
limit). For fixed-dose combinations and SP, ‘‘pass’’ was awarded
only if both active ingredients met this standard.
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